



Stereotaxis to Report Third Quarter 2016 Financial Results on November 7, 2016

November 2, 2016

ST. LOUIS, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 third quarter ended September 30, 2016 on Monday, November 7, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.

- What:** Stereotaxis third quarter 2016 financial results conference call
- When:** Monday, November 7th at 4:30 p.m. Eastern Time (1:30 p.m. PT)
- Dial In Number:** To access the live call, dial **888-349-9582** (US and Canada) or **719-457-2506** (International) and give the participant pass code **3880603**.
- Webcast:** To access the live and replay webcast, please visit the investor relations section of Stereotaxis' website at www.stereotaxis.com
- Call Replay:** A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Monday, November 14, 2016. To access the replay dial-in information, please click [here](#).

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core *Epoch*[®] Solution includes the *Niobe*[®] ES remote magnetic navigation system, the *Odyssey*[®] portfolio of lab optimization, networking and patient information management systems, and the *Vdrive*[®] robotic navigation system and consumables.

The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono[™] ICE catheter manipulator, V-Loop[™] variable loop catheter manipulator, and V-CAS[™] catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect[™] catheter advancement system has been CE Marked for sale in the European Union. For more information, please visit www.stereotaxis.com.

Press Contact:
Martin Stammer
Chief Financial Officer
314-678-6155

Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com



Stereotaxis, Inc.